Gefitinib therapy for advanced non-small-cell lung cancer.

about

An approach to evaluating drug-nutrient interactions.Induction of Na+/K+/2Cl- cotransporter expression mediates chronic potentiation of intestinal epithelial Cl- secretion by EGF.

P2860

Q36320632-30B7A773-55FD-433B-9CE5-D5A39B3D3EF3 Q39993492-58AE663D-1C09-4F0C-B10E-784098FEE075

P2860

Gefitinib therapy for advanced non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q35562614

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Gefitinib therapy for advanced non-small-cell lung cancer.

@ast

Gefitinib therapy for advanced non-small-cell lung cancer.

@en

type

Item

label

Gefitinib therapy for advanced non-small-cell lung cancer.

@ast

Gefitinib therapy for advanced non-small-cell lung cancer.

@en

prefLabel

Gefitinib therapy for advanced non-small-cell lung cancer.

@ast

Gefitinib therapy for advanced non-small-cell lung cancer.

@en

P1476

Gefitinib therapy for advanced non-small-cell lung cancer.

@en

P2093

Chin Y Liu

http://www.w3.org/2001/XMLSchema#string

Susan Seen

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2002

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

ZD1839 ('Iressa') as an anticancer agent.

Tyrosine kinase inhibitors-ZD1839 (Iressa).

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

Targeting epidermal growth factor receptor in lung cancer.

P304

1644-1653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1D145

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9044808

http://www.w3.org/2001/XMLSchema#string

P698

14565788

http://www.w3.org/2001/XMLSchema#string

Gefitinib therapy for advanced non-small-cell lung cancer.

about

P2860

P2860

Gefitinib therapy for advanced non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698